Diffuse large B-cell lymphoma (DLBCL) is an aggressive disease whose management is complex and requires open communication amongst a multidisciplinary care team. It has a high rate of relapse, with up to 40 percent of patients relapsing within the first two years after primary treatment. Management of a patient with DLBCL begins with prognostic evaluation of the disease and assessing the potential adverse effects of treatments. It should be followed by evaluations of physical, physiological, cognitive, and socio-economic status of the patient. When considering treatment options, the patient should be engaged to share their expectations and goals related to disease control and quality of life.

CANCER BUZZ spoke to Robin Atkins, RN, OCN, symptom triage nurse, Virginia Oncology Associates in Norfolk, Virginia. Listen as we discuss effective practices to support patients with diffuse large b-cell lymphoma throughout the care continuum.

"It's important to listen for meaning when talking with patients and caregivers who are undergoing cancer treatments for diffuse large b-cell lymphoma and incorporating that into the care plan."

"Need to validate the patient perspective."

"Shared decision-making is a two-way conversation."

Robin Atkins, RN, OCN

Symptom Triage Nurse

Virginia Oncology Associates

Norfolk, Virginia

Resources:

Cancer Support Community

Leukemia & Lymphoma Society

This project is supported by AbbVie/Genmab and Genentech.